Abandoned trial: only 2 patients tested for stomach relief in muscle disease

NCT ID NCT04226170

Terminated Symptom relief Sponsor: DAS-MG, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small, early-stage trial tested whether adding ondansetron (an anti-nausea drug) to pyridostigmine (a standard myasthenia gravis treatment) could reduce stomach side effects like nausea, vomiting, or diarrhea. Only 2 people with anti-AchR positive myasthenia gravis were enrolled before the study was terminated. The goal was to improve quality of life by making the main treatment more tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ondansetron and pyridostigmine
What this could lead to: If it works, this could help manage stomach side effects from standard myasthenia gravis medication, making treatment easier to tolerate.
What could go wrong: The trial was terminated early with only 2 participants, so results are very limited. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Show contact details

Locations

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.